| 4.86 -0.03 (-0.61%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.23 | 1-year : | 7.28 |
| Resists | First : | 5.34 | Second : | 6.23 |
| Pivot price | 4.73  |
|||
| Supports | First : | 4.33 | Second : | 3.71 |
| MAs | MA(5) : | 4.88 |
MA(20) : | 4.62 |
| MA(100) : | 4.88 |
MA(250) : | 5.56 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 58.2 |
D(3) : | 62.4 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 11 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ UNCY ] has closed below upper band by 30.7%. Bollinger Bands are 60.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.01 - 5.05 | 5.05 - 5.07 |
| Low: | 4.78 - 4.82 | 4.82 - 4.85 |
| Close: | 4.8 - 4.87 | 4.87 - 4.92 |
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Tue, 14 Oct 2025
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - Sahm
Mon, 13 Oct 2025
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Mon, 13 Oct 2025
The Gross Law Firm Notifies Shareholders of Unicycive Therapeutics, Inc.(UNCY) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar
Mon, 13 Oct 2025
Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. Investors - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 30.5 (%) |
| Shares Short | 1,170 (K) |
| Shares Short P.Month | 1,280 (K) |
| EPS | -2.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51 % |
| Return on Equity (ttm) | -131.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -1.78 |
| PEG Ratio | 0 |
| Price to Book value | 4.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|